THE BIG SALE IS ON! TELL ME MORE

Close Notification

Your cart does not contain any items

Data Science, AI, and Machine Learning in Drug Development

Harry Yang

$221

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Chapman & Hall/CRC
03 October 2022
The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change.

Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations.

Features

Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise

Edited by:  
Imprint:   Chapman & Hall/CRC
Country of Publication:   United Kingdom
Dimensions:   Height: 234mm,  Width: 156mm, 
Weight:   620g
ISBN:   9780367708078
ISBN 10:   0367708078
Series:   Chapman & Hall/CRC Biostatistics Series
Pages:   320
Publication Date:  
Audience:   Professional and scholarly ,  College/higher education ,  Undergraduate ,  Further / Higher Education
Format:   Hardback
Publisher's Status:   Active

Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).

Reviews for Data Science, AI, and Machine Learning in Drug Development

"""The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."" Ramzi El Feghali, ISCB News, May 2024."


See Also